Also trades as: 1672.HK (HKSE) · $vol 3M
ASCLF OTC
Ascletis Pharma Inc.
1W: -13.3%
1M: -18.8%
3M: -30.7%
YTD: -30.2%
1Y: -14.8%
3Y: +73.3%
5Y: +173.7%
$1.04
-0.08 (-7.14%)
Weekly Expected Move ±10.3%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$342M
-136.9% ▼
Capital Expenditures
$2M
+88.8% ▲
5Y CAGR: -40.3%
Free Cash Flow
-$344M
-110.5% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$99M
-24.8% ▼
Net Change in Cash
$534M
+825.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$209M | -$199M | -$315M | -$145M | -$301M |
| Depreciation & Amort. | $27M | $30M | $30M | $18M | $20M |
| Stock-Based Comp. | $5M | $7M | $3M | $1M | $3M |
| Change in Working Capital | $10M | -$10M | $34M | $39M | $14M |
| Other Non-Cash Items | -$40M | -$22M | $105M | -$58M | -$78M |
| Operating Cash Flow | -$85M | -$147M | -$142M | -$144M | -$342M |
| — Investing Activities — | |||||
| Capital Expenditures | -$39M | -$7M | -$14M | -$6M | -$2M |
| Acquisitions (Net) | -$20M | $2M | $0 | $0 | $0 |
| Investment Purchases | -$75M | -$602M | -$1.8B | -$997M | -$638M |
| Investment Sales | $191M | $332M | $479M | $1.2B | $1.5B |
| Other Investing | $76M | $254K | $92K | -$13M | $121M |
| Investing Cash Flow | $132M | -$274M | -$1.3B | $150M | $979M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$2M | -$2M | -$2M | -$2M | -$5M |
| Stock Repurchased | -$20M | -$29M | $0 | -$79M | -$99M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$135K | -$125K | -$157K | -$144K | -$244K |
| Financing Cash Flow | -$22M | -$31M | -$1M | -$81M | -$104M |
| Net Change in Cash | -$85M | -$483M | -$1.3B | -$74M | $534M |
| Cash End of Period | $2.2B | $1.7B | $404M | $330M | $864M |
| Free Cash Flow | -$124M | -$154M | -$157M | -$163M | -$344M |